Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 21 | 18 | −3 |
| Shares | 181.9K | 119.7K | −62.2K (−34.2%) |
| Value | $674.2K | $185.5K | −$488.8K (−72.5%) |
New holders (1)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 23 | $36 | 0.00% |
Sold out (4)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 20,000 | $74.0K |
| McGuire Capital Advisors Inc | 1,000 | $3.71K |
| Advisory Services Network, LLC | 59 | $219 |
| Citigroup Inc | 1 | $4 |